[June 28, 2016]

Hormone Replacement Therapy (HRT) - Global Strategic Business Report 2016-2022: Amid Controversies, Confusion and Competition, Demand for HRT Continues to Rise - Research and Markets

Research and Markets has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering.

The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Thousand.

The report profiles 40 companies including many key and niche players such as

• Abbott Laboratories (US)
• AbbVie, Inc. (US)
• Allergan plc (Ireland)
• Hisamitsu Pharmaceutical Co., Inc. (Japan)
• Noven Pharmaceuticals, Inc. (US)
• Novartis AG (Switzerland)
• Novo Nordisk A/S (Denmark)
• Orion Pharma AB (Finland)
• Pfizer, Inc. (US)
• Rottapharm Madaus (Italy)
• Teva Pharmaceutical Industries Ltd. (Israel)
• TherapeuticsMD, Inc. (US)

1. Outlook

2. Industry Overview

3. Market Trends & Issues

4. Competitive Landscape

5. Therapy Profile - A Review Of Select Recent Studies Conducted

6. Product Overview

7. Product Introductions/Approvals

8. Recent Industry Activity

9. Focus On Select Global Players

10. Global Market Perspective

Total Companies Profiled: 40 (including Divisions/Subsidiaries 47)

• The United States (22)
• Canada (3)
• Japan (3)
• Europe (12)
• - Germany (1)
• - The United Kingdom (5)
• - Rest of Europe (6)
• Asia-Pacific (Excluding Japan) (6)
• Middle East (1)

For more information visit http://www.researchandmarkets.com/research/4nqktk/hormone

View source version on businesswire.com: http://www.businesswire.com/news/home/20160628005686/en/

[ Back To TMCnet.com's Homepage ]